Viewing Study NCT02650895

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 2:13 PM

Ignite Modification Date: 2026-02-06 @ 2:38 PM

Study NCT ID: NCT02650895

Status: COMPLETED

Last Update Posted: 2023-01-12

First Post: 2016-01-06

Is Gene Therapy: True

Has Adverse Events: True

Brief Title: Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

Sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module Adverse Events Module Baseline Characteristics Module Participant Flow Module